Yinxiang Wang

Yinxiang Wang (王印祥) is chairman and CEO of Jacobio Pharmaceuticals (加科思), a biotech company he has led through its transition from early-stage R&D to commercialization . Under his leadership, Jacobio secured a partnership with AstraZeneca and brought its drug goleresib (戈来雷塞) to market in 2025, which Wang described as marking the company's entry into commercial operations . He has also publicly positioned Jacobio's work on oral treatments for autoimmune diseases as addressing a gap in a market dominated by antibody injections . elsewhere's corpus does not cover his background prior to Jacobio or biographical details beyond his role at the company.